Sonnet BioTherapeutics Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Sonnet BioTherapeutics Holdings has a total shareholder equity of $2.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.3M and $2.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.02m |
| Equity | US$2.57m |
| Total liabilities | US$2.77m |
| Total assets | US$5.34m |
Recent financial health updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Financial Position Analysis
Short Term Liabilities: SONN's short term assets ($4.6M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: SONN's short term assets ($4.6M) exceed its long term liabilities ($111.0K).
Debt to Equity History and Analysis
Debt Level: SONN is debt free.
Reducing Debt: SONN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SONN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SONN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.4% each year